Fig. 3From: Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysisForest plot comparing LVEF improvement and MACE risks: intracoronary vs. intravenous glycoprotein IIb/IIIa inhibitors (a) LVEF, (b) MACE, (c) heart failure, (d) reinfarction, (e) target vessel revascularization, and (f) strokeBack to article page